Cancer News and Research

Latest Cancer News and Research

Scientists use gold-filled silicon wafers to target and burn breast cancer cells

By shining infrared light on specially designed, gold-filled silicon wafers, scientists at The Methodist Hospital Research Institute have successfully targeted and burned breast cancer cells. If the technology is shown to work in human clinical trials, it could provide patients a non-invasive alternative to surgical ablation, and could be used in conjunction with traditional cancer treatments, such as chemotherapy, to make those treatments more effective.

18 Jan 2012

LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG, IUCT and LEITAT announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.

18 Jan 2012

New research highlights and offers solutions for a nitrogen-soaked world

The nitrogen cycle has been profoundly altered by human activities, and that in turn is affecting human health, air and water quality, and biodiversity in the U.S., according to a multi-disciplinary team of scientists writing in the 15th publication of the Ecological Society of America's Issues in Ecology.

18 Jan 2012

Study explains how cells regulate their bonds during new blood vessel development

New research explains how cells regulate their bonds during the development of new blood vessels. For the first time, the role of the protein Raf-1 in determining the strength of the bond between cells has been shown.

18 Jan 2012

Study shows how to stop brain cancer cell proliferation and migration

Brain cancer is hard to treat: it's not only strong enough to resist most chemotherapies, but also nimble enough to migrate away from radiation or surgery to regrow elsewhere. New research at the University of Colorado Cancer Center shows how to stop both.

18 Jan 2012

Connection between Musashi1 and HuR proteins can lead to glioblastoma

Most research on glioblastoma development, a complicated tumor of the brain with a poor prognosis, has focused on the gene transcription level, but scientists suggest that post-transcriptional regulation could be equally or even more important.

18 Jan 2012

Innovative computer algorithm identifies clinically prognostic marker for cancer

Researchers at the Stanford University School of Medicine have used an innovative mathematical technique to find markers that effectively predict how deadly a cancer will be. The discovery, which in this case concerned bladder cancer, could lead to faster, less expensive and more accurate analysis of cancer risk and better treatment of the disease.

18 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Research reports on effectiveness of Scriptaid in breast cancer cell lines

Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.

18 Jan 2012

Study compares adoptive T-cell therapy with drug-based cancer treatment

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.

18 Jan 2012

Scientists identify hepsin protein's role in breast cancer

Cancers rarely are deadly unless they evolve the ability to grow beyond the tissues in which they first arise. Normally, cells -- even early-stage tumor cells -- are tethered to scaffolding that helps to restrain any destructive tendencies. But scientists from the University of Helsinki, Finland, and from UCSF have identified a cleaver-wielding protein that frees some tumor cells, allowing them to further misbehave.

18 Jan 2012

Researchers develop simple process for synthesis of artemisinin

The most effective anti-malaria drug can now be produced inexpensively and in large quantities. This means that it will be possible to provide medication for the 225 million malaria patients in developing countries at an affordable price. Researchers at the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universit-t Berlin have developed a very simple process for the synthesis of artemisinin, the active ingredient that pharmaceutical companies could only obtain from plants up to now.

18 Jan 2012

Voraxaze receives FDA approval for treatment of toxic methotrexate levels

The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.

18 Jan 2012

State roundup: State lawmakers, governors planning health legislation; Some Pa. kids losing Medicaid

Iowa House and Senate Republicans could support legislation requiring lawmakers to contribute to the cost of their state-provided health-care benefits, party leaders told the Des Moines Register's editorial board this morning. The health-care packages now offered by the state - in which most employees, including legislators, are not required to make contributions from their salaries - are "out of touch" with the plans available to average Iowans, ... House Speaker Kraig Paulsen, R-Hiawatha, said.

18 Jan 2012

Novelos initiates enrollment in HOT Phase 1b trial for advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has enrolled the first patient in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound (131)I-CLR1404 (HOT) in cancer patients with advanced solid tumors.

18 Jan 2012

'Pro-survival' protein inhibitors may improve outlook for AML patients

Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.

18 Jan 2012

Regorafenib lengthens lives of patients with metastatic colorectal cancer

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

17 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

Actavis, Scil Proteins sign Reteplase supply agreement

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase.

17 Jan 2012

Mentor executes long-term funding agreement to receive 50% ownership in Brighter Day Health

Mentor Capital, Inc. announced that it has executed a long-term funding agreement to receive a current 50% ownership in Brighter Day Health, LLC, pending their expected shareholder approval.

17 Jan 2012